B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co

Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, Germany and MONMOUTH JUNCTION, N.J., March 2, 2021 /PRNewswire/ — B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation […]

In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum

Stock Market News 2021-03-02

Nouvelles officielles de Cooperation 2024

Velocity Global's 2022 Work In Progress Report: Businesses and

Organization

Dental disaster: One year after first lockdowns dentists around

Continuous Renal Replacement Therapy (CRRT) Market Drivers & Opportunities

Nouvelles officielles de Cooperation 2024

B cells, plasma cells and antibody repertoires in the tumour microenvironment

B. Braun Melsungen AG Accelerates Digital Healthcare Innovations with MuleSoft - Salesforce

In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum

Digital Diabetes Management Market Size, Trends & Forecast